BeyondSpring (BYSI) Total Non-Current Liabilities (2019 - 2026)
BeyondSpring (BYSI) posted Total Non-Current Liabilities of $36.4 million for Q1 2026, little changed sequentially from $36.3 million in Q4 2025, and down 1.93% YoY from $37.1 million in Q1 2025.
BeyondSpring (BYSI) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends
BeyondSpring has reported Total Non-Current Liabilities for 8 years, with the latest figure at $36.4 million in Q1 2026.
- Quarterly Total Non-Current Liabilities fell 1.93% year-over-year to $36.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $36.4 million (down 1.93% YoY) and the FY2025 annual result came in at $36.3 million, down 3.31% from the prior year.
- Total Non-Current Liabilities was little changed at $36.4 million in Q1 2026 per BYSI's latest filing, from $36.3 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $41.9 million in Q4 2022 and troughed at $36.3 million in Q4 2025.
- A 5-year average of $38.5 million and a median of $37.6 million in 2024 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2022 and 2024: Total Non-Current Liabilities soared 400.99% in 2022, then fell 6.75% in 2024.
- Over 5 years, Total Non-Current Liabilities stood at $41.9 million in 2022, then decreased by 3.74% to $40.3 million in 2023, then dropped by 6.75% to $37.6 million in 2024, then declined by 3.31% to $36.3 million in 2025, then rose by 0.12% to $36.4 million in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $36.4 million, $36.3 million, and $36.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.76 Bn | 131.91 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 86.51 Bn | 78.51 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.74 Bn | 60.56 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 59.39 Bn | 54.26 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.24 Bn | 37.15 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.78 Bn | 28.47 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.65 Bn | 10.26 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.22 Bn | 26.39 Bn | - | 9.32 Bn |
| 10 | BeyondSpring | 29.61 Mn | 29.61 Mn | - | 36.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 36.44 Mn |
| Mar 31, 2026 | 36.39 Mn |
| Dec 31, 2025 | 36.35 Mn |
| Sep 30, 2025 | 36.40 Mn |
| Jun 30, 2025 | 36.86 Mn |
| Mar 31, 2025 | 37.11 Mn |
| Dec 31, 2024 | 37.59 Mn |
| Jun 30, 2024 | 38.99 Mn |
| Dec 31, 2023 | 40.31 Mn |
| Jun 30, 2023 | 40.74 Mn |
| Dec 31, 2022 | 41.88 Mn |
| Jun 30, 2022 | 40.92 Mn |
| Dec 31, 2021 | 40.12 Mn |
| Sep 30, 2021 | 40.65 Mn |
| Jun 30, 2021 | 8.17 Mn |
| Mar 31, 2021 | 8.90 Mn |
| Dec 31, 2020 | 11.45 Mn |
| Sep 30, 2020 | 3.65 Mn |
| Jun 30, 2020 | 3.80 Mn |
| Mar 31, 2020 | 3.31 Mn |